UPDATE: Deutsche Bank Raises PT on Neurocrine Biosciences Ahead of Key Catalysts

In a report published Thursday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Neurocrine Biosciences NBIX, and raised the price target from $15.00 to $25.00. In the report, Deutsche Bank noted, “Over the next 12 months we see four key catalysts that will provide upside to Neurocrine shares: Kinect Ph2, Kinect2 Ph2, Kinect safety, & Elagolix ph3 topline results. We also believe the opportunity for Elagolix in uterine fibroids (UF) is underappreciated. We have increased our probabilities for Elagolix in endometriosis (75% to 85%), VMAT2 (25% to 50%) to reflect trial successes over next 12 mo & raised Elagolix UF estimates. Maintain Buy.” Neurocrine Biosciences closed on Thursday at $14.40.